EVENTS · BMY
PEERS
EARNINGS
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions. Its portfolio includes small-molecule drugs, biologics, and cell therapies, reflecting a broad approach to advanced treatment design and delivery. The company supports healthcare systems through research-driven products used in hospitals, specialty clinics, and outpatient care settings around the world. Bristol-Myers Squibb Company plays an important role in the pharmaceutical market by providing therapies aimed at difficult-to-treat illnesses and by maintaining a diversified pipeline and product mix across multiple disease categories.
Drug makers rallied broadly after Amgen and Novo Nordisk both raised their full year forecasts on strong results, lifting sentiment across the group including Bristol-Myers Squibb
| Series | 1W | 1M |
|---|---|---|
| BMY | +6.0% | +7.7% |
| Peers | +6.9% | +14.2% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 58 | 48 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 1.21 | 1.35 | +11.57% | +3.15% |
| Q2 FY2026 | 1.60 | 2.04 | +27.20% | — |
| Q1 FY2026 | 1.43 | 1.58 | +10.40% | — |
| Q4 FY2025 | 1.13 | 1.26 | +11.85% | — |
| Q3 FY2025 | 1.52 | 1.63 | +6.93% | — |
| Series | 1W | 1M |
|---|---|---|
| BMY | +6.0% | +7.7% |
| Peers | +6.9% | +14.2% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 58 | 48 |
